Drug Trial Radar · NCT04644575
Long-term Safety and Efficacy of Efanesoctocog Alfa (BIVV001) in Previously Treated Patients With Hemophilia A
Last checked: Nov 19, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
261
Actual
Start
Feb 23, 2021
Primary completion
Jan 15, 2027
Study completion Jan 15, 2027
Sponsor
- Lead sponsor
- Bioverativ, a Sanofi companySanofi (SNY)
- Sponsor type
- Industry
- First posted
- Nov 25, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: \- To evaluate the long-term safety of BIVV001 in previously treated subjects with hemophilia A Secondary Objectives: * To evaluate the efficacy of BIVV001 as a prophylaxis treatment. * To evaluate the efficacy of BIVV001 in the treatment of bleeding episodes. * To evaluate BIVV001 consumption for prevention and treatment of bleeding episodes. * To evaluate the effect of BIVV001 prophylaxis on joint health outcomes. * To evaluate the effect of BIVV001 prophylaxis on Quality of Life (QoL) outcomes. * To evaluate the safety and tolerability of BIVV001 treatment. * To assess the PK of BIVV001 based on the one stage activated partial thromboplastin time (aPTT) and two-stage chromogenic FVIII activity assays (only applicable to Arm B). * To evaluate the efficacy of BIVV001 for perioperative management
Conditions
- Hemophilia A
Interventions
efanesoctocog alfa (BIVV001)Drug
Pharmaceutical form:Solution for Injection Route of administration: Intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with the occurrence of inhibitor development (neutralizing antibodies detected against factor VIII [FVIII])Time frame: Baseline to month 48
Locations
85 sites in 23 countries. Site status is shown where the registry gives one.
Orthopaedic Institute for Children Site Number : 8400003
Los Angeles, California
Children's Hospital Los Angeles Site Number : 8400009
Los Angeles, California
University of California San Diego Site Number : 8400007
San Diego, California
University of Florida Health Site Number : 8400008
Gainesville, Florida
Children's Healthcare of Atlanta Site Number : 8400016
Atlanta, Georgia
Rush University Medical Center Site Number : 8400010
Chicago, Illinois
Children's Hospital Of Iowa Site Number : 8400011
Iowa City, Iowa
University of Michigan Medical Center Site Number : 8400006
Ann Arbor, Michigan
Michigan State University School Of Med Site Number : 8400002
East Lansing, Michigan
Hemostasis and Thrombosis Center of Nevada Site Number : 8400001
Las Vegas, Nevada
New York Presbyterian Hospital/Weill Cornell Medical Center Site Number : 8400017
New York, New York
East Carolina University -2390 Hemby Ln Site Number : 8400015
Greenville, North Carolina
Cincinnati Children's Hospital Medical Center Site Number : 8400012
Cincinnati, Ohio
Children's Research Institute Site Number : 8400013
Columbus, Ohio
Bloodworks Northwest Site Number : 8400005
Seattle, Washington
Children's Hospital of Wisconsin Site Number : 8400014
Milwaukee, Wisconsin
Investigational Site Number : 0320003
Buenos Aires, Argentina
Investigational Site Number : 0320001
CABA, Buenos Aires F.D., Argentina
Investigational Site Number : 0320002
Godoy Cruz, Mendoza Province, Argentina
Investigational Site Number : 0360004
Camperdown, New South Wales, Australia
Investigational Site Number : 0360001
Westmead, New South Wales, Australia
Investigational Site Number : 0360002
South Brisbane, Queensland, Australia
Investigational Site Number : 0360003
Murdoch, Western Australia, Australia
Investigational Site Number : 0560003
Woluwe-Saint-Lambert, Belgium
Hemocentro Campinas - UNICAMP Site Number : 0760001
Campinas, São Paulo, Brazil
Investigational Site Number : 1000171
Plovdiv, Bulgaria
Investigational Site Number : 1000172
Sofia, Bulgaria
Investigational Site Number : 1240005
Hamilton, Ontario, Canada
Investigational Site Number : 1240004
Hamilton, Ontario, Canada
Investigational Site Number : 1240002
Ottawa, Ontario, Canada
Investigational Site Number : 1240001
Toronto, Ontario, Canada
Investigational Site Number : 1560002
Beijing, China
Investigational Site Number : 1560006
Beijing, China
Investigational Site Number : 1560001
Guangzhou, China
Investigational Site Number : 1560003
Hangzhou, China
Investigational Site Number : 1560004
Hangzhou, China
Investigational Site Number : 1560005
Jinan, China
Investigational Site Number : 1560009
Kunming, China
Investigational Site Number : 1560010
Kunming, China
Investigational Site Number : 1560013
Lanzhou, China
Showing 40 of 85 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.